Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

por Chen, Jian, Williams, Sandy, Ho, Samantha, Loraine, Howard, Hagan, Deborah, Whaley, Jean M., Feder, John N.
Publicado 2010

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

por Whaley, Jean M, Tirmenstein, Mark, Reilly, Timothy P, Poucher, Simon M, Saye, JoAnne, Parikh, Shamik, List, James F
Publicado 2012

SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic β-cell death in genetically obese mice

por Jurczak, Michael J., Saini, Saumya, Ioja, Simona, Costa, Diana K., Udeh, Nnamdi, Zhao, Xiaojian, Whaley, Jean M., Kibbey, Richard G.
Publicado 2018

Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus

por Reilly, Timothy P., Graziano, Michael J., Janovitz, Evan B., Dorr, Thomas E., Fairchild, Craig, Lee, Francis, Chen, Jian, Wong, Tai, Whaley, Jean M., Tirmenstein, Mark
Publicado 2014

SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function

por Jurczak, Michael J., Lee, Hui-Young, Birkenfeld, Andreas L., Jornayvaz, Francois R., Frederick, David W., Pongratz, Rebecca L., Zhao, Xiaoxian, Moeckel, Gilbert W., Samuel, Varman T., Whaley, Jean M., Shulman, Gerald I., Kibbey, Richard G.
Publicado 2011

Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody

por Hinke, Simon A., Cieniewicz, Anne M., Kirchner, Thomas, D'Aquino, Katharine, Nanjunda, Rupesh, Aligo, Jason, Perkinson, Robert, Cooper, Philip, Boayke, Ken, Chiu, Mark L., Jarantow, Steve, Lacy, Eilyn R., Liang, Yin, Johnson, Dana L., Whaley, Jean M., Lingham, Russell B., Kihm, Anthony J.
Publicado 2018